News Digest 16.10.2026 — 23.10.2026
Regulators
The government has amended the procedure for verifying the Russian origin of products manufactured by institutions and enterprises within the penal system (UIS)
A draft proposal presented by the Russian Ministry of Finance in September 2026 suggested establishing a distinct mechanism to verify the Russian origin of goods produced by penal system institutions and enterprises. This model was intended to apply to nearly all items listed in Appendices 1 and 2 of the government decree "On Measures to Provide a National Regime in Public Procurement"—a category that includes surgical medical devices, ventilators, medical furniture, pharmaceuticals, and more. The Ministry of Finance also proposed that this verification mechanism would not be required if, at the time of bid submission, the product in question was already included in the registry of Russian industrial products.
Simultaneously, it was proposed that the ban on procuring foreign-made goods should not apply to any products manufactured by penal system institutions or enterprises. In the final version of the document, this scope has been narrowed to specific categories: clothing, fur products, tanned and dressed leather, suitcases, bags, and footwear.
The provision governing the calculation of the initial contract price remains unchanged from the original draft. The adopted amendments stipulate that when procuring goods, the contracting authority must request price information for "each item included in the procurement object" from at least three industrial operators that manufacture the relevant products and are registered in the state industrial information system. The previous version of the regulations used more general, less specific language.
Nevertheless, as noted by experts from the National Analytical and Expert Center for Healthcare (NAECZ), this new approach to determining the initial contract price does not apply to the procurement of pharmaceuticals and medical devices. For these entities, the Initial Maximum Contract Price (IMCP) is determined in accordance with procedures established by the Ministry of Health, as stipulated by Federal Law No. 44-FZ "On the Contract System in the Procurement of Goods, Works, and Services for State and Municipal Needs." The Ministry of Finance and the Ministry of Industry and Trade have previously confirmed this, and regional offices of the Federal Antimonopoly Service (FAS) follow the same practice, the National Association of Experts in Public Procurement (NAETsZ) noted.
In August 2026, the government amended a resolution concerning "national regime" measures in public procurement. It categorized support measures for products manufactured within the Eurasian Economic Union (EAEU) into two sections of the list of vital and essential medicines (VED/SZLS), which had been updated in April 2026. Although the changes were initially scheduled to take effect in July 2026, the final version of the document pushed the implementation date to December of this year.
Lawmakers propose raising the age limit for children to be hospitalized alongside a parent
A bill has been submitted to the State Duma of the Russian Federation to amend Articles 51 and 80 of the Federal Law "On the Fundamentals of Health Protection of Citizens in the Russian Federation." The authors of the initiative propose raising the age limit—from four to eight years—for children whose parents or legal guardians are guaranteed the right to stay with them in a medical facility free of charge. If enacted, the law would come into effect on June 1, 2027.
The explanatory memorandum notes that separation from family causes significant stress for a child, which hinders the recovery process. Furthermore, given the shortage of junior medical staff, parents often end up taking on some of the care responsibilities for children aged 4 to 7—for instance, by helping to ensure that medication is administered and that the daily routine is followed.
According to the financial and economic assessment, implementing this measure would require additional funding. The estimated cost ranges from 9.2 billion to 13.1 billion rubles per year. This calculation is based on Rosstat data (approximately 1.09 million hospital admissions per year for children aged 4–7) and an average daily rate of 1,500 rubles for an additional bed and meals, assuming a hospital stay of seven to ten days. The lawmakers propose covering these costs through the federal budget, noting that this would amount to only about 0.02–0.03% of total federal expenditures.
The proposal to raise the age limit for children to be hospitalized alongside a parent was first introduced by lawmakers in October 2022. In an official opinion dated April 16, 2026—which is attached to the current proposal—the Russian government notes that similar bills have been considered in the past, and that the Cabinet of Ministers’ position on the matter remains unchanged.
Market news
Chinese companies have emerged as leaders in three out of five key segments of government procurement for laboratories
Products from Chinese companies dominate three of the five key segments of the Russian market for laboratory reagents and consumables. In 2025, the share of imported products in the category of in vitro diagnostic medical devices stood at 68.4%, while Russian-made products accounted for 31.6%.
Reagents make up three-quarters of the market, with the remainder consisting of analyzers, consumables, and auxiliary equipment. In the "Biochemistry" segment, the Chinese company Mindray leads with a 22.43% share. In total, suppliers from the PRC account for 24.4% of this segment, followed by Russia (19.4%) in second place, and the United Kingdom and Ireland (18.4%) tied for third.
In the "Hematology" segment, Chinese-made products account for 43.24% of the total volume (4.8 billion rubles). Russian manufacturers hold the second position (25.1%). Consequently, products from Russia and "friendly" nations make up more than 70% of all procurement in this category—primarily from companies with localized production (such as Boule, Lidkor, and Mindray).
In the "Hemostasis" segment, Russian manufacturers hold the leading position (30.7%). Notable players include the specialized firm Tekhnologiya-Standart, as well as other domestic manufacturers that also have a presence in other areas (such as Vector-Best, Abris+, etc.). Italy ranks second in this procurement segment (22.7%), followed by Germany (14.5%). Products from China account for only 9.68%.
In the "Blood Gases and Electrolytes" segment, the market is dominated by foreign manufacturers from "unfriendly" countries: Denmark (30.9%), the United States (20.8%), and Italy (17.9%). Combined, products from these three nations account for 69.73% of total procurement volume. The market leader in this category is Radiometer (Denmark), with a 30.93% share (valued at 2 billion rubles).
In the "Urinalysis" (urine chemistry) segment, companies from China lead the market (43.1%), followed by manufacturers from Japan (15%) and South Korea (10%). While the share held by Russian manufacturers remains negligible as of 2025, several ongoing projects offer the prospect of growth in the near future.
Earlier this year, manufacturers of medical devices and laboratory reagents requested material support and additional guarantees from the relevant government ministries. Specifically, they are seeking legislative provisions for minimum procurement quotas in the public sector, as well as financial guarantees for investors.
Siemens registers the world’s first photon-counting CT scanner in Russia
Roszdravnadzor (the Federal Service for Surveillance in Healthcare) has issued a registration certificate to the German company Siemens Healthineers for its NAEOTOM Alpha computed tomography (CT) scanner—the first device of its kind to utilize photon-counting technology. The system’s specialized detector measures individual X-ray photons as they pass through the patient’s body; the scanner then converts this data into a detailed three-dimensional image for medical professionals. The registration certificate has been issued indefinitely for two models of the device: Pro and Peak.
The initial NAEOTOM Alpha CT model was first approved by the U.S. Food and Drug Administration (FDA) in September 2021. At the time, the agency described the device’s release as "the first major technological breakthrough in computed tomography in the last decade." The system features two X-ray tubes, each capable of capturing 144 physical slices; it has a minimum tube rotation time of 0.25 seconds and a minimum slice thickness of 0.2 mm.
During the device's registration, Siemens explained that standard CT scanners convert X-rays into visible light, which is then detected by a light sensor to produce the final image. "Because of this intermediate step, important information regarding the energy of the X-rays is lost and becomes unavailable for diagnostic purposes—resulting in reduced contrast and less sharp images," the company stated.
In contrast, the new device does not convert X-rays into visible light; instead, X-ray photons are transformed directly into fully digital electrical signals, which are then counted without any loss of data. The German manufacturer emphasized that "this adds a wealth of entirely new, clinically significant information and enhances both image sharpness and contrast."
The scanner also incorporates "Quantum HD" spectral imaging technology, which allows for the visualization of an object using a specific spectral range, enabling the detection of minute anatomical details that would be invisible with conventional CT scanning.
According to Siemens, this innovative device has a wide range of applications—from oncology procedures and the diagnosis of heart conditions to follow-up lung examinations for respiratory diseases.
A 2.5 Billion Ruble Center for Plastic Surgery Products to be Established in Nizhny Novgorod
Construction has begun in Nizhny Novgorod on an innovative scientific and technological center called "Territory of Health" ("Territoriya Zdorovya"), which will encompass the full cycle of development, manufacturing, and implementation of domestic medical products for plastic surgery. The project is being carried out by Silnex JSC, a resident of the "Quantum Valley" (Kvantovaya Dolina) Innovative Scientific and Technological Center. The complex will span over 20,000 square meters, with construction divided into three phases. The total investment is estimated at more than 2.5 billion rubles.
The first phase is scheduled for completion in 2028. The research and production module is intended for the manufacture of breast, testicular, and gluteal implants, as well as hyaluronic acid and biodegradable fillers. The projected annual capacity is up to 45,000 silicone implants and up to 500,000 hyaluronic acid-based injectable products.
The second phase will focus on additive technologies and 3D printing, including the development of new implant designs and materials. The third phase involves the construction of a cluster of multidisciplinary clinics covering more than 14,000 square meters, designed for clinical trials of new products and the training of specialists.
The Institute of Plastic Surgery and Cosmetology serves as a key partner for the project across all stages—from development and manufacturing to clinical testing and professional training. Furthermore, scientific cooperation agreements have been signed between Silnex JSC and the Nizhny Novgorod Research Institute of Clinical Oncology (part of the "Health City" project), as well as between the Russian Society of Plastic, Reconstructive and Aesthetic Surgeons and the Ministry of Health of the Nizhny Novgorod Region. The "Quantum Valley" Innovation, Science and Technology Center (ISTC) project is managed by the Nizhny Novgorod Region Development Corporation.
Other
First spinal cord transplantation performed at the Sklifosovsky Research Institute
The Sklifosovsky Research Institute for Emergency Medicine has performed the first spinal cord transplantation in Russia. The procedure lasted 12 hours, according to Moscow Mayor Sergey Sobyanin. He noted that the patient, who faced the prospect of total immobility, now has a chance at recovery.
The surgery was carried out with the participation of Chinese colleagues as part of a medical technology transfer initiative. It follows a Moscow-based project focused on upper-limb transplantation.
In March 2026, a program for hand transplantation following limb loss was launched in Moscow. The total number of transplant procedures performed in the capital’s hospitals has more than doubled in recent years: 859 operations were conducted in 2025, compared to 428 in 2020.
New registered medical devices
We publish a list of new medical devices registered from 10.16.2026 to 10.23.2026
Link to the list: [see table in the attachment]
News
